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Abstract
Background Individualised risk prediction is crucial if targeted pre-operative risk reduction strategies are to be
deployed effectively. Radiologically determined sarcopenia has been shown to predict outcomes across a range of
intra-abdominal pathologies. Access to pre-operative cross-sectional imaging has resulted in a number of studies
investigating the predictive value of radiologically assessed sarcopenia over recent years. This systematic review and
meta-analysis aimed to determine whether radiologically determined sarcopenia predicts post-operative morbidity
and mortality following abdominal surgery.
Method CENTRAL, EMBASE and MEDLINE databases were searched using terms to capture the concept of
radiologically assessed sarcopenia used to predict post-operative complications in abdominal surgery. Outcomes
included 30 day post-operative morbidity and mortality, 1-, 3- and 5-year overall and disease-free survival and length
of stay. Data were extracted and meta-analysed using either random or fixed effects model (Revman 5.3).
Results A total of 24 studies involving 5267 patients were included in the review. The presence of sarcopenia was
associated with a significant increase in major post-operative complications (RR 1.61 95% CI 1.24–4.15
p =\0.00001) and 30-day mortality (RR 2.06 95% CI 1.02–4.17 p = 0.04). In addition, sarcopenia predicted 1-, 3-
and 5-year survival (RR 1.61 95% CI 1.36–1.91 p =\0.0001, RR 1.45 95% CI 1.33–1.58 p =\0.0001, RR 1.25
95% CI 1.11–1.42 p = 0.0003, respectively) and 1- and 3-year disease-free survival (RR 1.30 95% CI 1.12–1.52
p = 0.0008).
Conclusion Peri-operative cross-sectional imaging may be utilised in order to predict those at risk of complications
following abdominal surgery. These findings should be interpreted in the context of retrospectively collected data and
no universal sarcopenic threshold. Targeted prehabilitation strategies aiming to reverse sarcopenia may benefit
patients undergoing abdominal surgery.
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Despite significant improvements in surgical outcomes
over recent decades, morbidity and survival following
major abdominal surgery still poses challenges. In order to
deploy targeted pre-operative risk reduction strategies, risk
prediction needs to be accurate on an individual level. The
current risk prediction methods include the American
Society of Anaesthesiologists (ASA) classification [1],
physiological and operative severity score for the enu-
meration of mortality and morbidity (PPOSSUM) [2] and
cardiopulmonary exercise testing (CPET) [3]. These
methods amongst others either fail to account for the
functional status of patients, or require additional pre-op-
erative hospitals visits which may be costly, time-con-
suming and unavailable at certain sites. In addition,
targeted strategies may be deployed during the pre-opera-
tive period with the aim of reversing sarcopenia. Sar-
copenia, initially used to describe the loss of lean muscle
mass associated with ageing, is now well a documented
feature of systemic conditions including inflammatory
states, cancer, cachexia, chronic malnutrition and in
response to chemotherapy [4]. Sarcopenia leads to reduced
mobilisation, suboptimal deep breathing and inability to
perform simple activities of daily living [5, 6], partly
explaining the increased post-operative morbidity and
mortality observed in these patients.
Cross-sectional imaging is routinely performed pre-op-
eratively for the staging of cancer and pre-operative plan-
ning. Cross-sectional views of trunk musculature provide
an easily obtained objective method for estimating lean
muscle mass [7].
Availability of peri-operative cross-sectional imaging has
led to an increase in the number of observational studies
assessing the relationship between sarcopenia and surgical
outcomes. A number of studies have reported significantly
worse post-operative morbidity and mortality, as well as
reduced long-term survival, in patients with radiological
evidence of sarcopenia [8–13]. Whilst recent systematic
reviews have described the results of studies focusing on
specific gastrointestinal malignancies [14–16], to our
knowledge this is the first review and meta-analysis exam-
ining the predictive value of radiologically assessed lean
muscle mass in patients undergoing any abdominal surgery.
Method
Search strategy
The Meta-analysis of Observational Studies in Epidemiol-
ogy (MOOSE) and Preferred Reporting Items for Systematic
Review and Meta-analyses (PRISMA) were consulted
throughout this review. A qualified medical librarian con-
ducted the literature search. The following databases were
searched for relevant studies: CENTRAL (via Cochrane
Library September 2015), EMBASE (via OVID 1974 to
September 2015) and MEDLINE (via PubMed 1946 to
September 2015). The search strategy used text words and
relevant indexing to capture the concept of radiologically
assessed sarcopenia used to predict post-operative compli-
cations in abdominal surgery. The full search strategy can be
viewed in the supplementary material. The following trial
registers were searched: ClinicalTrials.gov (www.clin
icaltrials.gov September 2015), WHO International Clinical
Trials Registry Platform (www.who.int/ictrp September
2015) and UK Clinical Research Network Study Portfolio
(http://public.ukcrn.org.uk/search September/2015). A total
of 6526 records were retrieved after removal of duplicate
manuscripts. Searches did not exclude studies based on
publication status or language. Reference lists of key articles
and the grey literature were hand-searched.
Inclusion criteria
Inclusion criteria were established prior to the literature
search. Studies reporting the prevalence of sarcopenia and
outcomes in adult patients ([18 years) following abdomi-
nal surgery were sought. At least one of the following
outcomes was required: post-operative mortality (30 days
following surgery), post-operative complications, Clavien–
Dindo complications, critical care dependency, length of
stay, disease-free survival (recurrence of the primary
tumour or metastases in cancer patients), overall survival
and graft loss (transplantation).
Abdominal surgery was defined as surgery involving the
abdominal cavity, including patients undergoing gastroin-
testinal, hepatobiliary, pancreatic, endocrine, urological,
gynaecological and transplantation surgery for both elec-
tive and emergency indications. Assessment of lean muscle
mass was limited to studies reporting radiological assess-
ment methods, including computed tomography, magnetic
resonance and dual-energy X-ray absorptiometry.
Exclusion criteria
Patients undergoing abdominal interventions other than
surgery, including percutaneous radiological procedures
were excluded. Studies reporting lean muscle mass as a
continuous measure or failing to define a sarcopenic pop-
ulation were also excluded. Subcutaneous surgery not
breaching the peritoneum, including abdominoplasty, and
patients undergoing oesophagectomy via a thoracic




Following removal of duplicates, two investigators
screened abstracts independently, and those meeting the
inclusion criteria were selected for full-text review.
Data extraction
Data were extracted independently by two investigators and
discrepancies resolved following further review of the full
article. Extracted data included age, sex distribution, ethnic
characteristics, malignant status, site of primary pathology,
grade and stage of tumour, exposure to chemotherapy or
radiotherapy, imaging modality and image analysis tech-
nique, sex-specific muscle measures, body mass index
(BMI), length of stay, complications (any complication and
Clavien–Dindo grades), mortality, disease-free survival and
overall survival. Authors were contacted in order to obtain
raw data where summary data or odds or hazard ratios were
reported, or if any further data clarification was required.
Quality assessment
Investigators independently reviewed each full-text article,
assessing quality using the Newcastle–Ottawa assessment
scale for each of the outcome measures.
Risk of bias assessment
The Cochrane collaboration risk of bias assessment tool
(chapter 8.5a) was used with additional domains relevant to
this review. Domains included image capture, training of
assessor, inter-observer reliability, selection bias, allocation
concealment, blinding of assessors, incomplete outcome data
and selective reporting. Each domain was allocated either a
low, unclear or high-risk score and summary data presented
using the traffic light system. Funnel plots for each meta-
analysis were visually inspected and interpreted in the context
of the individual comparisons (Supplementary Fig. 1).
Heterogeneity assessment
Heterogeneity was estimated using Cochran’s Q statistic,
and the percentage of variation in meta-analysed outcomes
that could be attributed to sources other than sampling error
(I2) also was calculated. An I2[ 50% was considered to
represent a chance of substantial heterogeneity, and[75%
considerable heterogeneity.
Sensitivity analysis
Where the weighting of individual studies within meta-
analyses was deemed to be significant ([25%), sequential
removal and analysis was performed. Significant results
were those resulting in a p value that was no longer sig-
nificant. If there were significant heterogeneity in terms of
study population, additional sensitivity analyses were per-
formed as described above.
Statistical analysis
Freeman–Tukey arcsine transformation was applied for
analyses where abstracted proportions had values of zero or
one [17]. Heterogeneity amongst study estimates was
quantified using the I2 and associated test for heterogeneity.
Where significant heterogeneity ([75%) was apparent, the
DerSimonian and Laird random effects [18] method was
used to pool estimates, with inverse-variance weights.




A total of 8272 records were identified from database
searching, of which 24 were included in the review
[8–10, 20–38]. Nine studies involved patients undergoing
hepatobiliary surgery, 4 pancreatic surgery, 4 colorectal
surgery, 3 urological surgery, 2 oesophago-gastric surgery
and 2 transplant surgery (liver). Five authors were con-
tacted via email on at least two separate occasions to
request clarification or to provide further data, three authors
responded with raw data which was included in the meta-
analysis. The PRISMA flow diagram can be seen in Fig. 1,
which includes the reasons for removal of studies.
Quality, bias and heterogeneity assessment
All of the studies were cohort studies, and quality was high
(median 8, range 5–9, see Table 1). A number of param-
eters in the risk of bias assessment were not reported and
therefore scored as unclear. Where bias was assessed, it
was generally determined to be low risk, with selection
bias being the most frequently reported high-risk domain
(Table 2). Following inspection of funnel plots for all
analyses, asymmetry was apparent for total complications.
An absence of studies in the bottom left side of the plot
suggests the possibility of reporting bias, where small
studies demonstrating no risk reduction in non-sarcopenic
patients are not published. This asymmetry may also be
explained by true heterogeneity as those studies towards
the right-hand side of the plots represent hepatobiliary





All of the included studies used computed tomography to
quantify muscle mass, with no alternative quantification
methods used in studies excluded following full-text
review. In addition, all included studies used the third
lumbar vertebra as the landmark for muscle measurement.
Alternative landmarks used in other studies include L4
[39], the umbilicus [40] and iliac crests [41]. A majority of
studies used image quantification software to calculate
surface area, manually drawing around the border of the
muscle, or alternatively measuring the antero-posterior and
transverse diameter [10]. Quantification by either a trained
assessor or radiologist was reported in eight studies
[10, 23, 33, 34, 37, 38, 42, 43]. Most used either total
lumbar muscle area (TLA) or total psoas area (TPA) with
one study using total psoas volume [34] and one using both
TPA and TPV [8]. All area measurements were corrected
for patient height (Table 1). Sarcopenia was defined as lean
muscle mass below a specific threshold based on either
previously published parameters or internally derived
based upon sensitivity analyses. Thirteen (54%) of the
Records Identified through 
database searching (n=8272)
Records Identified through other 
sources (n=2)
Records after duplicates 
removed (n=6526)
Records screened (n=6526) Records removed 
(n=6467)








Surgery in general, not 
abdominal specific 2
Fat measurements only 
- 1
Muscle measured after 
surgery - 2
Fat only measured - 1
Thoracic surgery - 2
Complication only at one 
year - 1
Tertile not sarcopenic 
analysis - 3
Quartile specific analysis 
(only bottom one and 
top one) - 1






LMM used as a 
continuous variable, no 
definition of sarcopenia -
2
Mixed surgical and non-
surgical approaches - 2
Articles included (n=24)
Fig. 1 PRISMA flow diagram
showing identification of studies





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































included studies used previously published thresholds to
define sarcopenia [9, 10, 12, 13, 21, 28, 32, 37, 38, 44–46],
whilst the remaining 11 (44%) defined sarcopenia inter-
nally [8, 22, 26, 29–31, 34, 36, 43, 47, 48]. Sex-specific
thresholds were frequently calculated in-house for each
study based on the local population, with values for TPA
ranging from 391 to 414 mm2/m2 in women, and 468 to
562 mm2/m2 in men. For TLA, values ranged from 370 to
414 mm2/m2 in women, and 437 to 550 mm2/m2 in men.
The median values were 475 mm2/m2 for men and
386 mm2/m2 for women. The largest thresholds were
reported in Western study populations [13], with the dif-
ference between Western and Asian populations prompting
Higashi et al. [21] to use different thresholds within their
study cohort.
Patient demographics and clinicopathological data
A total of 5267 patients were included across the 24 studies.
Thirty-five percentage (1820) patients were sarcopenic, with
rates varying from 15% (colorectal [10]) to 66% (liver
transplantation [28]). Median age was 65 years, and 60% of
patients were male. Ninety-three percentage (4876) patients
were operated on for malignancy, with the remaining
patients undergoing liver transplantation for both malignant
and benign indications [26, 28]. Of the patients who were
staged using the TNMclassification, 12% (359)were stage 1,
40% (1137) stage 2, 38% (1078) stage 3 and 10% (298) stage
4. Thirty-three percentage (613) had well-differentiated
tumours, 56% (1037) moderately differentiated tumours and
11% (217) poorly differentiated tumours.
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Total complications included all Clavien–Dindo graded
complications as well as all other study specific compli-
cations. There was a 15% increased risk of any compli-
cation, with 54% of sarcopenic patients suffering
complications compared with 37% of non-sarcopenic
patients (RR 1.15 95% CI 1.04–1.28 p = 0.009), though
there was significant heterogeneity amongst studies (I2
67%, see Fig. 2). The greatest effect size was seen in
colorectal and hepatobiliary surgery (RR 1.75 95% CI
1.06–2.87 p = 0.03, OR 1.72 95% CI 1.15–2.58
p = 0.008, respectively). Sarcopenia increased the risk of
major complications (Clavien–Dindo[ grade 3) by 61%,
with 25% of sarcopenic patients suffering major compli-
cations compared with 16% of non-sarcopenic patients
(95% CI 1.24–4.15 p =\0.00001 I2 43%, see Fig. 3).
Following subgroup analysis, although there was a 7%
increased risk of major complications in patients under-
going pancreatic surgery, which failed to reach significance
(95% CI 0.83–1.39 p = 0.61, see Fig. 3). The baseline
characteristics, including tumour stage and grade, were
comparable across the three studies involving pancreatic
surgery [8, 30, 49]. Of note, the study period overlaps for
the cohorts included in the studies by Peng et al. [30] and
Amini et al. [8], attributed to the same institution. The
more recent report by Amini et al. [8] used total psoas
volume to quantify muscle mass, compared with psoas
cross-sectional area which was used by the previous study
by Peng et al. [8, 30]. Whilst both methods determined
25% of patients to be sarcopenic, the volumetric technique
predicted both overall and major complications. Exclusion
of the earlier paper by Peng et al. from the subgroup
analysis reduced heterogeneity to 0% and increased the
relative risk from 9 to 33%, though this failed to reach
statistical significance (p = 0.09).
Fig. 2 Forest plots comparing overall (any) complications in sarcopenic versus non-sarcopenic patients. A Mantel–Haenszel fixed effects




The presence of sarcopenia significantly increased the risk
of post-operative mortality with 2.7% of sarcopenic
patients dying within 30 days compared with 0.8% in the
non-sarcopenic group (RR 2.06 95% CI 1.02–4.17
p = 0.04, see Fig. 4). Sarcopenia was also associated with
an increased risk of 90-day mortality (10% sarcopenic vs.
2.5% non-sarcopenic, RR 3.66 95% CI 2.10–6.38
p =\0.0001, Supplementary Fig. 2) with no heterogeneity
in both analyses (I2 0%, see Fig. 4).
1-, 3- and 5-year mortality
Sarcopenia predicted 1-, 3- and 5-year survival, with the
risk decreasing from 61% for 1-year, 45% for 3-year and
25% for 5-year (29% sarcopenic vs. 18% non-sarcopenic
RR 1.61 95% CI 1.36–1.91 p =\0.0001 (1-year), 66%
sarcopenic vs. 45% non-sarcopenic RR 1.45 95% CI
1.33–1.58 p =\0.0001 (3-year), 50% sarcopenic vs. 56%
non-sarcopenic RR 1.25 95% CI 1.11–1.42 p = 0.0003 (5-
year), see Fig. 5). Studies reporting 1-, 3- and 5-year sur-
vival included liver (1019), pancreas (1022) and transplant
(169) patients. In addition, median overall survival was
shorter in patients with sarcopenia in 8 from a total of 10
studies [11, 20, 31, 34, 37, 43, 47, 50], ranging from 17.7 to
69.7 months in sarcopenic patients, to 18–146 months in
non-sarcopenic patients (Supplementary Fig. 3). In the 2
studies where median survival in sarcopenic patients
exceeded non-sarcopenic patients, the difference was non-
significant [8, 45].
Fig. 3 Forest plots comparing major (Clavien–Dindo[ 3) complications in sarcopenic versus non-sarcopenic patients. A Mantel–Haenszel
fixed effects model was used to meta-analyse the data. Subgroup analysis has been performed for colorectal (1.2.1), hepatobiliary (1.2.2),
pancreatic (1.2.3) and urological surgery (1.2.4)
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Fig. 4 Forest plot comparing 30-day mortality in sarcopenic versus non-sarcopenic patients. A Mantel–Haenszel fixed effects method was
used to meta-analyse the data
Fig. 5 Forest plots comparing overall survival in sarcopenic versus non-sarcopenic patients. The first plot presents 1-year survival, the second




All five studies reporting disease-free survival included
patients with malignant disease. One-year disease-free
survival was significantly worse in patients with sarcope-
nia, with 55% of sarcopenic patients suffering recurrence
compared with 45% of non-sarcopenic patients (RR 1.30
95% CI 1.12–1.52 p = 0.0008, see Fig. 6). Whilst the risk
was increased for 3-year disease-free survival (81% sar-
copenic vs. 80% non-sarcopenic, RR 1.04 95% CI
0.96–1.13 p = 0.04, see Fig. 6), the relative risk increase
was significantly reduced at 4%, and for 5-year disease-free
survival, there was no difference between sarcopenic and
non-sarcopenic groups (RR 1.06 95% CI 1.00–1.13
p = 0.06, see Fig. 6).
Length of stay
Ten studies including 2766 patients reported data pertain-
ing to length of hospital stay. Length of stay was increased
in patients with sarcopenia in 8 studies, with 6 identifying a
significant difference (see supplementary Fig. 4). The
remaining two studies showed no significant difference in
length of stay between sarcopenic and non-sarcopenic
patients [30, 35]. There were also comparable overall
complications [30] and major complications [35] between
sarcopenic and non-sarcopenic patients in these studies
including oesophago-gastric and pancreatic cancer patients.
In addition, three of the studies collected data on intensive
care unit (ICU) stay, reporting significantly increased ICU
stay in patients with sarcopenia [24, 29, 51, 52].
Discussion
This meta-analysis of 24 studies including 5267 patients
aimed to determine the predictive value of radiologically
determined sarcopenia for outcomes following abdominal
surgery. Lean muscle mass was quantified using peri-op-
erative cross-sectional imaging and the presence of sar-
copenia predicted post-operative complications, mortality,
1-, 2- and 5-year overall survival and 1- and 3-year disease-
Fig. 6 Forest plots comparing disease-free survival in sarcopenic versus non-sarcopenic patients. The first plot presents 1-year survival, the
second 3-year survival and the third 5-year survival. A Mantel–Haenszel fixed effects method was used to meta-analyse the data
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free survival. In addition, sarcopenia was frequently asso-
ciated with increased length of stay and intensive care
dependency. The inclusion of patients undergoing any
abdominal surgery in this study facilitated meta-analytical
evaluation of the data, the first reported to our knowledge.
Nearly all (93%) patients included in the analysis
underwent oncological resection surgery, the remainder
being transplant recipients with significant comorbidities
[11, 53]. The paucity of evidence available for non-onco-
logical surgery is likely due to the incidence of post-op-
erative morbidity following major resectional surgery,
where risk prediction may result in the greatest overall
benefit to patients. There are limited data available on
radiologically quantified lean muscle mass in the normal
population, which is reflected in the lack of robust criteria
for defining sarcopenia based on these measurements.
Investigators have responded by determining their own
thresholds based upon local populations and sensitivity
analyses. Joglekar et al. suggested the introduction of a
universal cut-off value for defining sarcopenia. However,
given the heterogeneity in prevalence amongst different
populations, it may be more appropriate to continue cal-
culating the thresholds based on local demographics.
Independent muscle quantification fails to take into
account the corresponding functional status of patients.
Although the relationship is assumed, none of the included
studies performed an assessment of muscle function. The
correlation is clearer when muscle loss results from ageing
[54], but is likely to be part of more complex interactions in
cancer patients where cachexia and chemotherapeutic
agents may affect function as well as volume [55]. In an
attempt to improve predictive sensitivity, some investiga-
tors have sought to take advantage of 3D imaging and
software programmes by calculating total muscle volume
and adjusting for fatty infiltration and the presence of blood
vessels using Hounsfield Units, with encouraging results
[8, 34]. Accounting for fatty infiltration may go some way
in mitigating the inability of volume alone to predict
function. In a weighted risk stratification score developed
by Wagner et al. [56], Hounsfield unit average calculation
alone improved sensitivity in an elderly population
undergoing hepatobiliary surgery. In studies using total
psoas volume (TPV), the measurement technique involved
measuring the cross-sectional area at sequential slices to a
total of 55cms psoas length. This was then corrected for
patient height and resulted in a sarcopenia prevalence of
48.9% and 19.9%, respectively, compared with 45.8 and
25.1 as measured by total psoas area (TPA) alone in the
same patients [8, 34]. In both of these studies, TPV was
better at predicting outcomes following surgery and
remained so following multivariate analysis. We were
unable to identify studies specifically reporting the number
of patients determined sarcopenic by one method but not
the other. The emerging data, however, would suggest that
volumetric measurements combined with density analyses
might be more sensitive.
Sarcopenia was a more significant predictor of major
complications (61%) compared with overall complications
(15%). In terms of respiratory and thromboembolic com-
plications, this may be as a result of reduced deep breathing
and mobilisation. In cases of sepsis, anastomotic leaks and
other major complications that are less likely to be asso-
ciated with functional status, this may reflect the underly-
ing functional and nutritional status of the patient. We were
unable to find any reports examining the link between loss
of muscle and the status of the primary lesion on a bio-
logical level. However, an association between primary
tumour biology and the extent of sarcopenia is supported
by the reduction in effect size over time in terms of both
overall and disease-free survival. Whilst sarcopenia pre-
dicted 1-, 3 and 5-year mortality, the risk reduced over time
(61, 34 and 25%, respectively). A similar pattern was
observed for disease-free survival. This supports the sug-
gestion that any observed loss in muscle mass is likely as a
result of a combination of factors associated with the
presence of malignancy. There are insufficient data from
patients with benign disease along with a lack of any fol-
low-up muscle measurements to fully support this theory.
Following subgroup analysis, sarcopenia failed to sig-
nificantly predict overall and major complications in
patients undergoing pancreatic surgery. Study by Peng
et al. was the only study in the pancreatic subgroup failing
to show increased morbidity in the sarcopenic group [30].
The authors themselves are unable to explain this finding,
but suggest it may be due to the inherently low compli-
cation rate in their high-volume centre. Interestingly, a
more contemporary report from the same institution using
total psoas volume to determine lean muscle mass found
that sarcopenia was associated with both overall and major
complications. When the previous study using cross-sec-
tional area measurement is removed from the subgroup,
significance is still not reached (p = 0.09). This finding is
somewhat difficult to explain, especially in light of
emerging evidence suggesting that sarcopenia is strongly
associated with the development of post-operative pan-
creatic fistula formation, a leading cause of morbidity in
patients undergoing pancreatic resection [57, 58].
On inspection of the funnel plot for total complications,
there is a suggestion of asymmetry towards greater sig-
nificance. There is an absence of smaller studies reporting
less significant effects. Whilst this may be explained by
publication bias, it may also be related to the outcome
measure being used to report the outcomes (Clavien–
Dindo). Clavien–Dindo accounts for complications ranging
from minor (I) through to death (V). Studies using the
classification for outcome coding may be expecting a
World J Surg
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higher incidence of serious complications, whilst studies
with few serious complications may not benefit from the
uniform coding of minor complications.
The abundance of emerging contemporary evidence
investigating the prognostic role of sarcopenia has resulted
in a number of recent review articles [14, 15, 59, 60]. With
focus on a specific abdominal malignancy in two such
reviews, including colorectal [61] and hepatobiliary sur-
gery [15], meta-analysis was precluded due to data
heterogeneity between the included studies. A recent
review by Shachar et al. examined the prognostic value of
sarcopenia in patients with solid organs tumours, irre-
spective of disease site. This allowed for meta-analysis and
included 7843 patients in total. A majority of the study
population comprised non-surgical patients with advanced
or metastatic disease. Interestingly, the relative risk
increase for overall survival in sarcopenic patients was not
significantly different between non-metastatic, metastatic
or mixed cohorts. These findings, along with our results,
suggest that the aetiology of sarcopenia in cancer popula-
tions is multifactorial and tumour burden may be one of
many contributing factors. Of note, sarcopenia failed to
predict overall survival in the pancreaticobiliary subgroup.
Whilst the patients are different from the surgical popula-
tion, with metastatic or advanced disease, these results are
in keeping with our findings. Although this analysis pro-
vides useful insight into the prognostic value of sarcopenia
in cancer patients, it cannot address the question of whether
sarcopenia predicts post-operative complications and
mortality.
Sarcopenia as a concept in surgical risk prediction is
attractive due its potential reversibility. In elective surgical
patients, there is a small window of opportunity from the
point at which scans are acquired to the date of surgery.
The approach during this period should be multi-faceted
and targeted to the individual patient. A combination of
strategies targeting inflammation, reduced exercise capac-
ity, secondary anorexia and reduced food intake have been
suggested in the context of cancer-related cachexia
[62, 63]. In the targeting of muscle mass and strength, the
largest body of evidence relates to ageing and muscle loss.
A number of studies have reported modest increases in
mass and capacity following relatively short anaerobic
resistance training [64–67]. Whilst reduced length of stay
and critical care dependency has been observed in cardio-
thoracic patients receiving prehabilitation programmes,
there are limited data examining the subsequent impact on
post-operative outcomes following abdominal surgery
[68–70]. In addition, cost-effectiveness and patient satis-
faction needs to be accounted for if pre-operative inter-
ventions are to be considered by budget commissioners. In
order to properly address the question of whether preha-
bilitation in sarcopenic patients can reduce complications
and mortality following surgery, clinical trials need to be
considered.
Limitations of this study include the retrospective
observational nature of the included articles. In addition,
based on funnel plot analysis, the results may be affected
by publication bias.
The majority of included studies used muscle volume
thresholds to define sarcopenia based on individual study
populations. Whilst this accounts for inherent geographical
differences, the limited generalisability means thosewishing
to further investigate sarcopenia may need to perform
internal sensitivity analyses in order to determine thresholds.
Conclusion
In conclusion, these data support a role for radiologically
determined sarcopenia in post-operative prognostication.
The retrospective nature of included studies, along with the
lack of consensus surrounding sarcopenic thresholds, limits
the generalisability of the results. Nonetheless, there may
be a potential role for targeted pre-operative interventions
in sarcopenic patients aimed at improving post-operative
outcomes. Future work needs to determine the efficacy of
interventions targeting muscle mass and function in the
pre-operative setting. In addition, the benefit of sarcopenia
reversal in surgical patients would need to be investigated
using prospective trial designs.
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